Gilead Sciences (GILD)
NASDAQ:GILD
GILD Stock Chart & Stats
$138.11
-$0.76(-0.84%)
At close: 4:00 PM EST
$138.11
-$0.76(-0.84%)
Day’s Range― - ―
52-Week Range$93.37 - $157.29
Previous CloseN/A
Volume1.95M
Average Volume (3M)6.96M
Market Cap
$171.45B
Enterprise Value$188.48B
Total Cash (Recent Filing)$10.61B
Total Debt (Recent Filing)$24.59B
Price to Earnings (P/E)17.9
Beta0.36
Next Earnings
Apr 23, 2026EPS Estimate
1.9Next Dividend Ex-DateN/A
Dividend Yield2.52%
Share Statistics
EPS (TTM)1.86
Shares Outstanding1,241,420,500
10 Day Avg. Volume6,440,160
30 Day Avg. Volume6,955,083
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)6.75
Price to Sales (P/S)5.19
P/FCF Ratio16.15
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue6.40
Enterprise Value/Gross Profit7.92
Enterprise Value/Ebitda14.62
Forecast
1Y Price Target
$158.00Price Target Upside14.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)8.68
Revenue Forecast (FY)$30.22B
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline ProgressPhase I results for the long-acting integrase candidate showed a clear dose response with higher doses maintaining protective drug levels for several months, prompting advancement into Phase II and reducing overall program risk when combined with an approved capsid inhibitor.
PrEP Launch And Market UptakeAnalyst notes Yeztugo's launch is showing robust uptake with payor coverage mobilizing faster than expected and gaining share versus a competing injectable, supporting significant PrEP sales potential.
Strategic Acquisition And Oncology ExpansionAcquisition of Arcellx grants full economic rights to anito-cel and adds a proprietary D‑Domain CAR platform plus an early-stage pipeline across liquid and solid tumors and select non-oncology indications, strengthening long-term revenue diversification.
Bears Say
Balance Sheet LeverageNet debt relative to equity is elevated, creating potential leverage risk that could limit financial flexibility and weigh on investor confidence.
Launch Logistics And Patient RetentionClinic-level injection logistics and uncertainty about patient return rates for follow-up doses could slow adoption of long-acting therapies and temper expected revenue growth.
Operating Costs And R&D SpendingHigher selling, general and administrative costs and increased in-process research and development spending have offset revenue strength, creating near-term margin pressure.
Gilead Sciences News
GILD FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was $93.37 and its highest was $157.29 in the past 12 months.
What is Gilead Sciences’s market cap?
Gilead Sciences’s market cap is $171.45B.
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Apr 23, 2026 which is in 29 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Feb 10, 2026. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.81 by $0.05.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of $0.79 which represents an annual dividend yield of 2.52%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is 1.9.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,241,420,500 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of $1.86 in its last earnings report, beating expectations of $1.81. Following the earnings report the stock price went up 5.821%.
Which hedge fund is a major shareholder of Gilead Sciences?
Currently, no hedge funds are holding shares in GILD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gilead Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$158.00 (14.40% Upside)
$158.00 (14.40% Upside)
Blogger Sentiment
Bullish
GILD Sentiment 84%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 94%
Bearish news 6%
Bearish news 6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.67%
12-Months-Change
Fundamentals
Return on Equity
41.01%
Trailing 12-Months
Asset Growth
0.05%
Trailing 12-Months
Company Description
Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
GILD Company Deck
GILD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial execution (notably in HIV treatment and prevention, liver, and Trodelvy) and a robust, diversified late-stage pipeline with multiple near-term catalysts and disciplined financial management. These positives were balanced against clear near-term headwinds: policy-driven pricing impacts (Part D/Medicaid/ACA), a substantial decline in COVID-related Vecluri revenue, and competitive pressures in cell therapy expected to reduce Kite revenues in 2026. Management reiterated conservative discipline on M&A and continued commitment to shareholder returns. Overall, company achievements, pipeline momentum, and outperformance against guidance materially outweigh the headwinds, which are largely known, quantified, and described as manageable.View all GILD earnings summariesGILD Revenue Breakdown
70.48% HIV
10.93% Liver Disease
3.09% Veklury
10.99% Oncology
2.71% Other
1.79% Royalty, contract and other revenues
GILD Stock 12 Month Forecast
Average Price Target
$158.00
▲(14.40% Upside)
Technical Analysis
Ownership Overview
0.09% Insiders
28.22% Mutual Funds
17.51% Other Institutional Investors
26.91% Public Companies and Individual Investors